Clinical and prognostic value of hypertensive cardiac damage in the PAMELA Study

Cesare Cuspidi1,2, Carla Sala3, Anna Casati1

  • 1Department of Medicine and Surgery, University of Milano-Bicocca, Milano, Italy.

Insights

Subclinical cardiac damage, like left ventricular hypertrophy, indicates higher cardiovascular risk. The PAMELA study assessed these changes and their prognostic impact in the general population.

Area of Science:

  • Cardiology
  • Cardiovascular Research
  • Clinical Epidemiology

Background:

  • Subclinical cardiovascular structural changes reflect cumulative damage from risk factors.
  • These alterations represent an intermediate stage between risk factor exposure and clinical events.
  • Such damage is a recognized marker of increased cardiovascular risk in various populations.

Purpose of the Study:

  • To assess normal values and prognostic significance of ambulatory and home blood pressure.
  • To investigate the prevalence, correlates, and prognostic value of subclinical cardiac alterations.
  • To review findings on cardiac abnormal phenotypes from the PAMELA study.

Main Methods:

  • The Pressioni Monitorate e Loro Associazioni (PAMELA) study enrolled a representative Northern Italian general population sample.
  • Data collection included ambulatory blood pressure monitoring, home blood pressure monitoring, electrocardiography (ECG), and echocardiography (ECHO).
  • Analysis focused on clinical aspects and prognostic significance of cardiac abnormal phenotypes.

Main Results:

  • The PAMELA study extensively investigated subclinical cardiac alterations.
  • Findings cover the prevalence and clinical correlates of phenotypes like left ventricular hypertrophy.
  • The prognostic value of these cardiac abnormalities was also extensively examined.

Conclusions:

  • Subclinical cardiac structural changes are significant indicators of cardiovascular risk.
  • The PAMELA study provides valuable insights into blood pressure monitoring and cardiac health.
  • Understanding these phenotypes is crucial for risk stratification in the general population.

Related Concept Videos

Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
690
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
682
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.4K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
603
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.2K
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
362